The authors have declared that no competing interest exists.
Pyridoxine HCl plays an important role in the human body as a coenzyme in the synthesis process of amino acids and neurotransmitters such as serotonin, norepinephrine, aminolevulinic acid, sphingolipids, etc. The objective of this study was to determine the effect of the Trivedi Effect®-Consciousness Energy Healing Treatment on the various physicochemical and thermal properties of pyridoxine HCl using various analytical techniques such. The study plan involved dividing the pyridoxine HCl sample into two parts, in which, the first part was not given any treatment (control sample), while the second part was provided the Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Gopal Nayak and named as the Biofield Energy Treated pyridoxine. The particle size values of the treated pyridoxine was altered by -19.51% (d10), -11.92% (d50), 2.46% (d90), and -2.44% {D(4,3)}; whereas, the surface area was significantly increased by 18.92%, compared to the control sample. The powder X-ray diffraction data showed the remarkable increase in the peak intensities and crystallite sizes of the treated pyridoxine in the range from 8.81% to 21.57% and 9.64% to 17.85%, respectively compared to the control sample. Moreover, the treated pyridoxine also showed an increase in the average crystallite size by 13.69%, compared to the control sample. The total weight loss of the treated pyridoxine was significantly reduced by 13.35% during the thermal degradation; however, the residue weight was increased by 29.48% after degradation, in comparison to the control sample. The maximum thermal degradation temperature of the treated pyridoxine corresponding to 1st and 2nd peak was altered by 4.37% and 2.24%, respectively than the control sample. The latent heat of fusion of the treated pyridoxine was significantly increased by 5.89% compared to the control sample. Hence, it was assumed that the Trivedi Effect®-Consciousness Energy Healing Treatment might form a new polymorph of pyridoxine HCl that might be helpful in designing more efficacious pharmaceutical/nutraceutical product due to its better solubility, absorption, bioavailability, and thermal stability than the untreated sample.
Vitamin B6 occurs in the nature in the form of pyridoxine, which after absorption in the gastrointestinal tract, converted to a form of coenzyme, pyridoxal phosphate
The test sample pyridoxine HCl was purchased from Tokyo Chemical Industry Co. Ltd., Japan but the other chemicals used in the experiment were purchased in India.
The test sample, i.e., pyridoxine HCl was divided into two equal parts. One part of pyridoxine was considered as a control sample where no Biofield Energy Treatment was provided. However, the second part of pyridoxine was received the Consciousness Energy Healing Treatment (the Trivedi Effect®) remotely under standard laboratory conditions for 3 minutes by the renowned Biofield Energy Healer, Gopal Nayak, India, and known as the Biofield Energy Treated pyridoxine. The control sample was treated by a “sham” healer who did not have any awareness about the Biofield Energy Treatment. After the treatment, both the samples were kept in sealed conditions and characterized using sophisticated analytical techniques.
The particle size analysis (PSA) of pyridoxine HCl was performed with the help of Malvern Mastersizer 2000, from the UK using the wet method
G = kλ/βcosθ(1)
Where G is the crystallite size in nm, λ is the radiation wavelength, k is the equipment constant, β is the full-width at half maximum, and θ is the Bragg angle
Similarly, the thermal gravimetric analysis (TGA)/ differential thermogravimetric analysis (DTG) thermograms of pyridoxine were obtained with the help of TGA Q50 TA instruments. The differential scanning calorimetry (DSC) analysis was performed with the help of DSC Q200, TA instruments
The % change in particle size, surface area, peak intensity, crystallite size, weight loss, degradation temperature, melting point, and latent heat of the treated pyridoxine was calculated compared with the control sample using the following equation 2:
The particle size analysis was done and the observed data were presented in
Parameter | d10 (µm) | d50 (µm) | d90 (µm) | D(4,3)(µm) | SSA(m2/g) |
Control | 9.89 | 41.54 | 129.37 | 58.26 | 0.37 |
Biofield Energy Treated | 7.30 | 36.88 | 133.41 | 57.31 | 0.44 |
Percent change (%) | -19.51 | -11.92 | 2.46 | -2.44 | 18.92 |
d10, d50, and d90: particle diameter corresponding to 10%, 50%, and 90% of the cumulative distribution, D(4,3): the average mass-volume diameter, and SSA: the specific surface area.
Besides, the analysis of the specific surface area of the treated pyridoxine showed that the surface area (0.43 m2/g) was increased by 18.92% after the Biofield Energy Treatment, as compared with the control sample (0.37 m2/g). In recent days the emphasis was done on improving the absorption and bioavailability of the drug by modifying the physicochemical properties of the crystalline compound and thereby increasing the surface area
The PXRD analysis was done for the control and treated samples of pyridoxine HCl and the corresponding diffractograms were recorded from diffraction analysis as given in
Entry No. | Bragg angle (°2θ) | Intensity (cps) | Crystallite size (G, nm) | |||||
Control | Treated | Control | Treated | % change |
Control | Treated | % change |
|
1 | 10.12 | 10.25 | 128 | 155 | 21.09 | 297 | 350 | 17.85 |
2 | 16.73 | 16.86 | 51 | 62 | 21.57 | 334 | 381 | 14.07 |
3 | 20.52 | 20.68 | 840 | 914 | 8.81 | 350 | 403 | 15.14 |
4 | 24.81 | 24.95 | 1172 | 1398 | 19.28 | 374 | 422 | 12.83 |
5 | 27.59 | 27.73 | 985 | 1145 | 16.24 | 384 | 421 | 9.64 |
denotes the percentage change in the relative intensity of the treated pyridoxine with respect to the control sample
denotes the percentage change in the crystallite size of the treated pyridoxine with respect to the control sample.
It was observed that the treated pyridoxine showed some alterations in the Bragg’s angles of the characteristic peaks of the PXRD diffractograms as compared to the control sample. Also, the treated pyridoxine showed a significant increase in the peak intensities as well as the crystallite sizes in the range from 8.81% to 21.57% and 9.64% to 17.85%, respectively as compared to the control sample. The significant change was also observed in the average crystallite size of the treated pyridoxine (395.40nm) after the Biofield Energy Treatment that was increased by 13.69% in comparison to the control sample (347.80nm). The changes in Bragg’s angles of the characteristic peaks along with the respective peak intensities and crystallite sizes compared to the untreated sample might be due to the changes in the crystalline pattern of the pyridoxine HCl after the Biofield Energy Treatment and there might be a new polymorph generated after the treatment
The TGA/DTG technique was used to determine the changes in the thermal degradation pattern of the treated pyridoxine in comparison to the control sample. The previous scientific studies on the thermogravimetric analysis of pyridoxine HCl reported its thermal stability below 150°C
Sample | TGA | DTG | ||
Total weight loss (%) | Residue % | Peak 1Tmax (°C) | Peak 2Tmax (°C) | |
Control | 68.83 | 31.17 | 217.80 | 387.69 |
Biofield Energy Treated | 59.64 | 40.36 | 208.28 | 379.01 |
% Change | -13.35 | 29.48 | -4.37 | -2.24 |
Tmax = the temperature at which maximum weight loss takes place in TG or peak temperature in DTG.
The DTG analysis showed the presence of two peaks in the thermograms of both the samples (
The DSC data indicate the changes in the enthalpy as well as any endothermic and exothermic events that might happen in the process of heating of the treated pyridoxine in comparison to the untreated sample
Sample | Peak Temperature (°C) | ∆H (J/g) |
Control | 215.42 | 304.09 |
Biofield Energy Treated | 215.42 | 322.00 |
% Change | 0.0 | 5.89 |
ΔH: Latent heat of fusion.
The significant change in the enthalpy of fusion of the treated pyridoxine might indicate some considerable changes in the molecular chain pattern and crystalline structure
The study was done on pyridoxine HCl to determine the impact of the Trivedi Effect®-Consciousness Energy Healing Treatment on its physicochemical and thermal properties as compared to the untreated pyridoxine. The Biofield Energy Treated pyridoxine showed altered particle size values of the treated pyridoxine by -19.51% (d10), -11.92% (d50), 2.46% (d90), and -2.44% {D(4,3)}; whereas, the surface area was significantly increased by 18.92%, compared to the control sample. This results concluded the potential increase in the dissolution and solubility of the treated pyridoxine that might improve the bioavailability as compared to the control sample. The PXRD data showed the remarkable increase in the peak intensities and crystallite sizes of the Biofield Energy Treated pyridoxine in the range from 8.81% to 21.57% and 9.64% to 17.85%, respectively compared to the control sample. Moreover, the treated pyridoxine also showed an increase in the average crystallite size by 13.69%, compared to the control sample. Hence, the PXRD data suggested the possible changes in the crystalline structure as well as the crystalline properties of the treated pyridoxine that might occur due to the possible formation of a new polymorph of pyridoxine HCl. The total weight loss of the Biofield Energy Treated sample was significantly reduced by 13.35% during the thermal degradation; however, the residue weight was increased by 29.48% after degradation, in comparison to the control sample. The ΔHfusion of the Biofield Energy Treated pyridoxine was significantly reduced by 12.28% as compared to the control pyridoxine HCl sample. Thus, the thermal analysis concluded the reduced thermal degradation and improved ΔHfusion of the Biofield Energy Treated pyridoxine increased thermal stability as compared to the untreated sample. Hence, the complete study concluded that the Trivedi Effect®-Consciousness Energy Healing Treatment might improve the solubility, absorption, thermal stability, and bioavailability of the pyridoxine HCl sample by altering its physicochemical and thermal properties. Hence, the treated pyridoxine HCl may be considered beneficial in formulation development due to better prevention and treatment against various diseases such as microcytic anemia, electroencephalographic abnormalities, Crohn’s disease, celiac disease, ulcerative colitis, depression, impaired renal function, dermatitis with cheilosis, glossitis, carpal tunnel syndrome, premenstrual syndrome, childhood autism, sleep apnoea, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, etc.
The authors are grateful to Central Leather Research Institute, SIPRA Lab. Ltd., Trivedi Science, Trivedi Global, Inc., Trivedi Testimonials, and Trivedi Master Wellness for their assistance and support during this work.